[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Therapy Class Overview : Hepatitis C Virus Infection

October 2013 | 33 pages | ID: T60FB59D344EN
MP Advisors

US$ 1,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This year the first IFN-free drug options for HCV Genotype 2/3- Gilead’s Sofosbuvir/RBV (GS-7977, PDUFA Dec. 8, 2013) is expected to be approved and launched! By 2015 launch of Gilead’s Sofosbuvir/Ledipasvir (PhIII) and AbbVie/ Enanta’s (ABT-450r/ABT-472/ABT-333) should remove the need of IFN for GT1 genotype HCV patients as well!

Tapping the Bigger Market- ROW: Gilead is moving well towards offering the best treatment options to a broader HCV pt population WW. . Genotype 1 is common in Australia, China, Taiwan and other countries in North Asia, while genotype 6 is found in Vietnam and other Southeast Asian countries. In India and Pakistan, genotype 3 is predominant, while genotype 4 is found in Middle Eastern countries such as Egypt, Saudi Arabia and Syria. A PAN genotype effective drug is what most companies are trying to sequester in their pipeline. This report comprehensively covers the current Standard of Care, its limitations and Future options for the treatment of HCV infection.

What one would get if buy this report ?
Noteworthy progress in the Oral IFN –Free combinations for Treatment of HCV and ROW opportunity
Competitive Landscape - IFN-Free drugs
HCV Vaccines and their progress
Difficult to treat and drugs for HCV-HIV co infection
Market size opportunity to 2020


More Publications